| Bioactivity | A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC50: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD)[1]. |
| CAS | 1439488-21-7 |
| Formula | C18H16N2O2S |
| Molar Mass | 324.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stössel A, et al. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. J Med Chem. 2013 Jun 13;56(11):4580-96. |
A2AAR/hMAO-B-IN-1
CAS: 1439488-21-7 F: C18H16N2O2S W: 324.40
A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.